Modified Ce/Zr-MOF Nanoparticles Loaded with Curcumin for Alzheimer's Disease via Multifunctional Modulation
Yan Yang,Yiling Wang,Xinran Jiang,Jiahao Mi,Dizhang Ge,Yuna Tong,Yuxuan Zhu
DOI: https://doi.org/10.2147/ijn.s479242
IF: 7.033
2024-09-27
International Journal of Nanomedicine
Abstract:Yan Yang, 1, &ast Yiling Wang, 1, &ast Xinran Jiang, 1 Jiahao Mi, 1 Dizhang Ge, 2 Yuna Tong, 3 Yuxuan Zhu 1, 2 1 Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China; 2 Department of Pharmacy, People's Hospital of Aba Tibetan and Qiang Autonomous Prefecture, Aba, 624000, People's Republic of China; 3 Department of Nephrology, The Third People's Hospital of Chengdu, Chongqing Medical University, Chengdu, 610031, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuna Tong; Yuxuan Zhu, Email ; Introduction: Alzheimer's disease (AD), a neurodegenerative condition, stands as the most prevalent form of dementia. Its complex pathological mechanisms and the formidable blood-brain barrier (BBB) pose significant challenges to current treatment approaches. Oxidative stress is recognized as a central factor in AD, underscoring the importance of antioxidative strategies in its treatment. In this study, we developed a novel brain-targeted nanoparticle, Ce/Zr-MOF@Cur-Lf, for AD therapy. Methods: Layer-by-layer self-assembly technology was used to prepare Ce/Zr-MOF@Cur-Lf. In addition, the effect on the intracellular reactive oxygen species level, the uptake effect by PC12 and bEnd.3 cells and the in vitro BBB permeation effect were investigated. Finally, the mouse AD model was established by intrahippocampal injection of Aβ 1-42 , and the in vivo biodistribution, AD therapeutic effect and biosafety of the nanoparticles were researched at the animal level. Results: As anticipated, Ce/Zr-MOF@Cur-Lf demonstrated efficient BBB penetration and uptake by PC12 cells, leading to attenuation of H 2 O 2 -induced oxidative damage. Moreover, intravenous administration of Ce/Zr-MOF@Cur-Lf resulted in rapid brain access and improvement of various pathological features of AD, including neuronal damage, amyloid-β deposition, dysregulated central cholinergic system, oxidative stress, and neuroinflammation. Conclusion: Overall, Ce/Zr-MOF@Cur-Lf represents a promising approach for precise brain targeting and multi-target mechanisms in AD therapy, potentially serving as a viable option for future clinical treatment. Keywords: metal-organic frameworks, Alzheimer's disease, drug delivery, brain targeting, oxidative stress Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive dysfunction and memory loss. 1 With the aging global population, AD incidence continues to rise. According to the World Alzheimer Report 2022, approximately 55 million people worldwide are currently affected by AD, a number expected to escalate to 139 million by 2050 if no effective interventions are developed. 2 Current treatments only alleviate symptoms and do not cure the disease. This limitation is partly due to the complex and not fully understood mechanisms underlying AD. Notably, two pathological hallmarks of AD are extracellular senile plaques composed of amyloid beta (Aβ) and intracellular neurofibrillary tangles caused by hyperphosphorylated tau protein (pTau). 3,4 Unfortunately, most therapeutic candidates targeting Aβ and pTau have failed to improve cognitive functions in phase II or III clinical trials, 5,6 casting doubt on the long-standing dominance of the Aβ and pTau hypotheses. Consequently, there is a critical need to explore other potential therapeutic targets, such as oxidative stress, to develop more effective treatments for AD. Recently, the oxidative stress hypothesis has gained attention due to its strong connection with the development of AD. This hypothesis highlights the link between the overproduction of reactive oxygen species (ROS) and AD progression. 7 Key sources of ROS in AD include damaged mitochondria, 8 abnormal metal homeostasis, 9 and activated microglia. 10 The gradual accumulation of ROS leads to sustained oxidative stress, a common physiological change in the early stages of AD brains. This stress disrupts the metabolism of biomacromolecules, Ca 2+ and energy homeostasis, mitochondrial function, and synaptic activity, ultimately resulting in cognitive decline. 7 Consequently, oxidative stress is often considered as a core factor in the early phases of AD, 11 potentially preceding other pathological features such as Aβ and tau pathology. 7,12 Moreover, -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology